Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1871-1878

  Laurie, Scott A ^a   Gauthier, Isabelle ^a   Arnold, Andrew ^a   Shepherd, Frances A ^a   Ellis, Peter M ^a   Chen, Eric ^a   Goss, Glenwood ^a   Powers, Jean ^a   Walsh, Wendy ^a   Tu, Dongsheng ^a   Robertson, Jane ^a   Puchalski, Thomas A ^a   Seymour, Lesley ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CEDIRANIB; PACLITAXEL; PROTEIN TYROSINE KINASE; VASCULOTROPIN INHIBITOR; 4 ((4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY) 6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINAZOLINE; 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-(PYRROLIDIN-1-YL)PROPOXY)QUINAZOLINE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ACNE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRY SKIN; FATIGUE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HEARTBURN; HUMAN; HYPERTENSION; HYPOTENSION; LIMB WEAKNESS; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; THORAX PAIN; THROMBOSIS; TREATMENT OUTCOME; VOICE CHANGE; VOMITING; WEAKNESS; ADULT; AGED; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; HEMATOLOGIC DISEASE; LUNG TUMOR; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC DISEASES; HUMANS; HYPERTENSION; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROTEIN-TYROSINE KINASES; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 42949105645     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.4741     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002
3. Fossella F, Pereira JR, von Powel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX326 study group. J Clin Oncol 21:3016-3024, 2003
4. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
5. Shepherd FA, Pereira JR, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
6. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
7. Bremnes RM, Camps C, Sirera R: Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51:143-158, 2006
8. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006
9. Manegold C, von Powel J, Zatloukal P, et al: Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small-cell lung cancer (NSCLC): BO17704. J Clin Oncol 25:388s, 2007 (suppl; abstr LBA7514)
10. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
11. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005
12. Drevs J, Siegert P, Medinger M, et al: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045-3054, 2007
13. Shields A, Heath E, DeLuca P, et al: AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study. J Clin Oncol 25:148s, 2007 (suppl; abstr 3544)
14. Goss GD, Laurie SA, Shepherd FA, et al: IND.175: phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small-cell lung cancer (ANSCLC): A study of the NCIC clinical trials group. J Clin Oncol 25:421s, 2007 (suppl; abstr 7649)
15. Chen EX, Jonker D, Gauthier I, et al: Phase I study of AZD2171 in combination with oxaliplatin and infusional 5-FU (mFOLFOX6) in patients with advanced colorectal cancer. Eur J Cancer 5:113, 2007 (suppl; abstr 92)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
17. Willey TA, Bekos EJ, Gaver RC, et al: High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J Chromatogr 621:231-238, 1993
18. Zufia L, Aldaz A, Castellanos C, et al: Simple and rapid determination of carboplatin in plasma by high-performance liquid chromatography. Error pattern and application to clinical pharmacokinetic studies. J Chromatogr B Biomed Sci Appl 764:457-464, 2001
19. Kendall MG: A new measure of rank correlation. Biometrika 30:81-93, 1938
20. Leighl N, Paz-Ares L, Douillard J, et al: Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada Clinical Trials Groups Study BR. 18. J Clin Oncol 23:2831-2839, 2005
21. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
22. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
23. Hurwitz H, Fehrenbacher L, Novotny WF, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
24. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001
25. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
26. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
27. Alberts SR, Morlan BW, Kim GP, et al: NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC): Interim review of toxicity. Proceedings of the 2007 Gastrointestinal Cancers Symposium, Orlando, FL, January 19-21, 2007 (abstr 186)
28. Sridhar S, Hotte S, MacKenzie MJ, et al: Phase II study of the angiogenesis inhibitor AZD2171 in first-line progressive unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH phase II consortium. J Clin Oncol 25:258s, 2007 (suppl; abstr 5093)
29. Ryan CJ, Stadler WM, Roth B, et al: Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs 25:445-451, 2007
30. Van Cruijsen H, Voest EE, Van Herpen CM, et al: Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors. J Clin Oncol 24:125s, 2006 (suppl; abstr 3017)
31. Shields A, Heath E, DeLuca P, et al: AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study. J Clin Oncol 25:148s, 2007 (suppl; abstr 3544)
32. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
33. Veronese ML, Mosenkis A, Flaherty KT, et al: Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363-1369, 2006
34. Curwen JO, Musgrove HL, Graham GA, et al: Management of hypertension induced by AZD2171, an oral, highly potent and reversible VEGFR signaling inhibitor, in rat. Clin Cancer Res 11:9034s, 2005 (suppl)
35. Rini BI, Tamaskar I, Shaheen P, et al: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83, 2007
36. Shepherd FA, Hasan B, Hicks L, et al: Venous thromboembolism (VTE) and non-small cell lung cancer (NSCLC): A pooled analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trials. Eur J Cancer 43:361, 2007 (suppl 5; abstr 6516)